Sarcoidosis - Pipeline Review, H2 2015

Date: September 9, 2015
Pages: 64
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SE6C38D73F2EN
Leaflet:

Download PDF Leaflet

Sarcoidosis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Sarcoidosis - Pipeline Review, H2 2015’, provides an overview of the Sarcoidosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sarcoidosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sarcoidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sarcoidosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sarcoidosis Overview
Therapeutics Development
Pipeline Products for Sarcoidosis - Overview
Pipeline Products for Sarcoidosis - Comparative Analysis
Sarcoidosis - Therapeutics under Development by Companies
Sarcoidosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Sarcoidosis - Products under Development by Companies
Sarcoidosis - Companies Involved in Therapeutics Development
Araim Pharmaceuticals Inc.
Celgene Corporation
FirstString Research, Inc.
Novartis AG
PharmaIN Corporation
Sarcoidosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABS-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-220 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cibinetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eprodisate disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGC-VIP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Sarcoidosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sarcoidosis - Recent Pipeline Updates
Sarcoidosis - Dormant Projects
Sarcoidosis - Discontinued Products
Sarcoidosis - Product Development Milestones
Featured News & Press Releases
Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA
Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy
Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring
Oct 10, 2013: Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sarcoidosis, H2 2015
Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Sarcoidosis - Pipeline by Araim Pharmaceuticals Inc., H2 2015
Sarcoidosis - Pipeline by Celgene Corporation, H2 2015
Sarcoidosis - Pipeline by FirstString Research, Inc., H2 2015
Sarcoidosis - Pipeline by Novartis AG, H2 2015
Sarcoidosis - Pipeline by PharmaIN Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Sarcoidosis Therapeutics - Recent Pipeline Updates, H2 2015
Sarcoidosis - Dormant Projects, H2 2015
Sarcoidosis - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Sarcoidosis, H2 2015
Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Araim Pharmaceuticals Inc.
Celgene Corporation
FirstString Research, Inc.
Novartis AG
PharmaIN Corporation
Skip to top


Ask Your Question

Sarcoidosis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: